Treatment schematic for patients with CLL at phase 2 dose. Patients received ublituximab infusions on day 1, 2, 8, and 15 of cycle 1, followed by a single infusion every 28 days on day 1 of cycles 2 to 6. Umbralisib was administered daily for cycles 1 to 12. Venetoclax was initiated on day 1 of cycle 4 with 5-week ramp-up and continued at target dose of 400 mg daily until the conclusion of cycle 12. Patients with undetectable MRD after cycle 12 discontinued treatment. Patients with detectable MRD continued umbralisib monotherapy until intolerance or progression.